PO.ET06.05 · 实验与分子治疗
胞质分裂蛋白调节因子1(PRC1)通过协调肿瘤-基质互作促进Wilms瘤进展
Protein regulator of cytokinesis 1 (PRC1) promotes Wilms tumor progression by orchestrating tumor-stromal crosstalk
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
Wilms瘤(WT)是最常见的儿童肾脏恶性肿瘤,也是儿童癌症相关发病率的主要原因。尽管多模式治疗取得了进展,具有高危组织学、复发疾病或双侧WT的患者仍然生存不良,并存在长期的治疗相关毒性。缺乏有效的靶向治疗凸显了迫切需要鉴定WT中新的致癌驱动因素和治疗脆弱性。我们采用整合系统生物学方法,包括加权基因共表达网络分析(WGCNA)以及跨TARGET和GEO数据集的生存分析,鉴定出胞质分裂蛋白调节因子1(PRC1)为一个与不良预后显著相关的基因。PRC1是纺锤体组织和胞质分裂的关键介导因子,已被发现与多种成人癌症相关,但其在Wilms瘤中的作用仍未明确。我们假设PRC1通过双重机制驱动Wilms瘤进展:(1)内在地通过beta-catenin/WT1轴促进肿瘤细胞增殖;(2)外在地通过WT细胞与癌症相关成纤维细胞(CAFs)之间的旁分泌信号重编程肿瘤基质。这些发现将为PRC1在儿童肾癌中的作用提供新的机制见解,并可能为未来的靶向治疗策略提供依据,以改善侵袭性或难治性Wilms瘤患儿的结局。
查看英文原文 English abstract
Wilms tumor (WT) is the most common pediatric renal malignancy and a major cause of cancer-related morbidity in children. Despite advances in multimodal therapy, patients with high-risk histology, relapsed disease, or bilateral WT continue to experience poor survival and long-term treatment-related toxicity. The absence of effective targeted therapies highlights the urgent need to identify new oncogenic drivers and therapeutic vulnerabilities in WT. Using integrative systems biology approaches, including Weighted Gene Co-expression Network Analysis (WGCNA) and survival analysis across TARGET and GEO datasets, we identified Protein Regulator of Cytokinesis 1 (PRC1) as a gene significantly associated with unfavorable prognosis. PRC1, a critical mediator of spindle organization and cytokinesis, has been implicated in multiple adult cancers, yet its role in Wilms tumor remains undefined. We hypothesize that PRC1 drives Wilms tumor progression by dual mechanisms: (1) intrinsically promoting tumor cell proliferation via the beta-catenin/WT1 axis, and (2) extrinsically reprogramming the tumor stroma through paracrine signaling between WT cells and cancer-associated fibroblasts (CAFs). These findings will provide new mechanistic insights into the role of PRC1 in pediatric kidney cancer and may inform future targeted therapeutic strategies to improve outcomes for children with aggressive or refractory Wilms tumors.
利益披露 Disclosure
Q. Wang, None.